截至2025年6月19日 09:37，恒生医疗保健指数(HSHCI)强势上涨1.32%，成分股信达生物(01801)上涨5.53%，晶泰控股(02228)上涨4.37%，诺诚健华(09969)上 涨3.46%，亚盛医药-B(06855)，美中嘉和(02453)等个股跟涨。恒生医疗ETF(513060)上涨1.26%，最新价报0.56元。流动性方面，恒生医疗ETF盘中换手 3.37%，成交2.71亿元。拉长时间看，截至6月18日，恒生医疗ETF近1周日均成交28.68亿元，居可比基金第一。 2025年6月20日-23日，第85届美国糖尿病协会科学会议（ADA）将在美国芝加哥召开，ADA大会是糖尿病研究与治疗领域的权威学术盛会之一，预计GLP-1 类药物的多靶点升级与减重治疗新策略将受到广泛关注。此次会议将有多家国内医药企业展示其在相关领域的最新研究成果和进展，建议关注。 国开证券指出，年初以来，创新药板块在政策、出海、业绩等多方面推动下，市场关注度高，叠加此前已经过较长时间调整，市场表现较为抢眼。目前个股 表现虽出现些许分化，但我们仍维持此前观点，认为创新药仍是行业最重要的投资主线之一。人工智能技术快速发展，医 ...

Core Insights - The article discusses the potential return of the prominent live-streaming influencer Viya, who has been absent for nearly four years, as she appears to be exploring private traffic channels through a new mini-program called "Qianxun Super Member" [1][2][5] - The mini-program has sparked speculation about Viya's comeback, despite the company behind it denying any plans for her to return to live streaming [1][5] - The trend of influencers shifting focus to private traffic is highlighted, as they seek new avenues for growth amid fierce competition in public traffic [2][5][13] Summary by Sections Viya's Potential Comeback - Viya has been linked to the "Qianxun Super Member" mini-program, which features her as a model in promotional materials, leading to speculation about her return [1][3] - The mini-program is currently in a testing phase, offering limited-time purchasing benefits for registered members, with various product categories available [3][4] Private Traffic Strategy - The article emphasizes the shift of top influencers towards private traffic as a strategy to maintain direct engagement with their fanbase and explore new monetization methods [5][12] - Viya's previous success in building a strong private traffic network is noted, with over 90,000 groups potentially reaching 1.8 million users [4][13] Industry Trends - The competitive landscape for top influencers is changing, with many seeking new growth opportunities in private traffic due to saturation in public traffic [5][13] - The challenges faced by other influencers, such as Xiaoyang Ge, in launching their own platforms and the difficulties in achieving significant traction are also discussed [11][12] Short Drama Ventures - Viya's company, Qianxun, is also venturing into the short drama space, attempting to leverage the popularity of short-form content for brand partnerships and advertising [7][8] - However, the initial results of these short dramas have been underwhelming, indicating the challenges of integrating influencer marketing with new content formats [8][12] Conclusion - The article concludes that the future success of influencers like Viya and Xiaoyang Ge in private traffic and new ventures will depend on their ability to engage and retain their fanbase, as consumer loyalty shifts towards product quality and pricing rather than individual personalities [14]

Core Insights - The acquisition of Baizhichui by Juyi Group marks a significant step in the company's strategy to expand into the scientific skincare sector, enhancing its multi-brand and multi-category beauty matrix [1][4] - The global functional skincare market is experiencing intense competition, with both international giants and local brands accelerating their presence in this lucrative segment [6][7] Company Overview - Juyi Group, established in 2016 and headquartered in Shanghai, owns two major color cosmetics brands, Judydoll and Jooycee, and has a partnership with Pierre Fabre Laboratories for the René Furterer brand in China [4] - The group reported a retail revenue exceeding 4.2 billion yuan and an income of 3.5 billion yuan in 2024, reflecting a year-on-year growth of 36% [4] Acquisition Details - Baizhichui, founded in 2012 and part of Meiji Biotechnology (Shanghai) Co., focuses on providing solutions for problematic and sensitive skin, emphasizing a "plant + technology" research approach [4][5] - Post-acquisition, Professor Li Yuanhong will continue as Chief Product Officer, overseeing the entire product development process, while co-founder and CEO Sun Hui will serve as a lifetime honorary advisor [5] Market Trends - The global professional skincare market reached a size of $35.77 billion in 2022, with projections to exceed $77.51 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.9% [6] - In China, the functional skincare sector saw a CAGR of 36.7% from 2017 to 2021, with a market size of approximately 46.43 billion yuan in 2022, marking a year-on-year growth of 22.9% [6] Competitive Landscape - Major global beauty companies like L'Oréal and Estée Lauder are increasingly investing in functional skincare through acquisitions and partnerships, indicating a strategic shift towards professional medical beauty [7][8] - Local brands such as Winona and Juzi Biotechnology are also capturing market share through differentiated strategies, with Juzi Biotechnology reporting a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.2% [8]

Core Viewpoint - The recent debate in the medical beauty industry regarding "recombinant collagen" has led to significant stock price fluctuations for leading companies, particularly Huaxi Biological and Juzhi Biological, with Huaxi denying any "business war" motives behind its actions [1][5]. Group 1: Market Reactions and Company Performance - From May 24 to June 18, Huaxi Biological's stock price increased by 23.65%, while Juzhi Biological's stock price fell by over 31% during the same period [1]. - As of June 18, Juzhi Biological's market capitalization was approximately 514 billion RMB, while Huaxi Biological's market capitalization was 245 billion RMB, less than half of Juzhi's [1]. Group 2: Opposition to "Name Games" - Huaxi Biological firmly opposes the "name game" in ingredient labeling, arguing that the capital market's concept switching has led to misunderstandings about hyaluronic acid and recombinant collagen, affecting the business environment and causing resource misallocation [2][3]. - The company emphasizes that recombinant collagen is only a small part of collagen research and that the leading edge of protein research remains with life science institutions and pharmaceutical companies [3]. Group 3: Industry Standards and Scientific Communication - Huaxi Biological highlights that no medical beauty Class III device certificates based on recombinant collagen have been approved internationally, indicating that this field requires more time for practical observation [3]. - The company plans to enhance professional communication with the capital market, noting that many analysts lack a biological background and often misinterpret the relationship between hyaluronic acid and collagen [4]. Group 4: Denial of Business War Claims - Huaxi Biological denies rumors that its recent actions are motivated by a "business war" due to pressure on its hyaluronic acid business and competition losses in recombinant collagen [5][6]. - The company asserts that its business has not been under pressure as claimed, with hyaluronic acid business growing over 10% annually and medical-grade hyaluronic acid growing over 20% [6]. Group 5: Consumer Trust and Market Integrity - Huaxi Biological argues that consumer trust in domestic brands should not be built on the misuse of academic concepts and misleading marketing practices, which could distort the business ecosystem and lead to resource misallocation [7]. - The company calls for industry-wide participation in product testing and standard discussions to enhance understanding and eliminate industry bubbles and misconceptions [7]. Group 6: Timeline of Events - The controversy began in mid-May when Huaxi Biological questioned several brokerage reports that promoted recombinant collagen and criticized hyaluronic acid [8]. - On May 24, beauty blogger "Big Mouth Doctor" Hao Yu publicly questioned the collagen content in Juzhi Biological's products, leading to further disputes [9][10].

Group 1 - The Hang Seng Medical ETF managed by Harvest has shown active trading with a turnover of 10.03% and a transaction volume of 28.177 million yuan, indicating a vibrant market activity [3] - As of June 17, the latest scale of the Hang Seng Medical ETF reached 282 million yuan, marking a new high in nearly a year, with a significant increase of 13 million shares over the past week [3] - The net inflow of funds into the Hang Seng Medical ETF was 11.5645 million yuan, with a total of 14.6068 million yuan accumulated over the last five trading days [3] Group 2 - The Hang Seng Medical ETF has achieved a net value increase of 56.06% over the past year, ranking 15th out of 119 QDII equity funds, placing it in the top 12.61% [3] - The ETF's highest monthly return since inception was 23.84%, with the longest consecutive monthly gains being four months and a maximum cumulative increase of 35.08% [3] - The average monthly return during the rising months was 7.62% [3] Group 3 - The Hang Seng Medical ETF closely tracks the Hang Seng Healthcare Index, which reflects the overall performance of healthcare-related securities listed in Hong Kong [4] - The top ten weighted stocks in the Hang Seng Healthcare Index include Innovent Biologics, BeiGene, WuXi Biologics, CSPC Pharmaceutical Group, CanSino Biologics, China National Pharmaceutical Group, JD Health, 3SBio, Hansoh Pharmaceutical, and Zai Lab, collectively accounting for 58.13% of the index [4] Group 4 - The Hong Kong stock market has performed well this year, with institutional investors believing that external disturbances have limited impacts on the fundamentals, and corporate earnings remain resilient [6] - The combination of domestic growth stabilization policies and improved global liquidity conditions is expected to support the Hong Kong stock market, potentially leading to new highs [6] Group 5 - Wanlian Securities suggests focusing on opportunities in the innovative drug sector, emphasizing high technical barriers and rapid iteration in niche markets, while also considering companies' R&D and commercialization capabilities [7] - The outlook for domestic high-end equipment and key raw materials is promising, with a recovery in biotech financing expected to boost orders for CXO companies [7] - Investors without stock accounts can consider the Hang Seng Medical ETF Harvest Connect Fund (018433) to gain exposure to investment opportunities in the Hong Kong healthcare sector [7]

美股回落,国际油价收涨超 4%，白银再破历 史高位 每日晨报 2025 年 6 月 18 日 银河观点集萃 责任编辑 周颖 ☎：010-80927635 网:zhouying_yj@chinastock.com.cn 分析师登记编码：S0130511090001 要闻 www.chinastock.com.cn 证券研究报告 请务必阅读正文最后的中国银河证券股份有限公司免责声明 机械：核电人形机器人专题报告——工业应用场景巡礼。国内核电人形机器人 ● 产业发展提速:自2024年3月起,国家地方共建人形机器人创新中心联合上 海电气中央研究院,针对核电行业极端环境需求,开展了大量技术攻关与联合 实验,成功部署首款针对核电产业日常生产的人形机器人并进驻核电场景训练 场,相关项目也顺利完成阶段性验收。同时,国家和上海、杭州、北京、深圳 等地纷纷出台人形机器人相关政策,从技术研发、应用推广等多方面给予支持, 为人形机器人深度融入核电产业、推动核电智能化发展奠定了坚实基础。核电 领域作为危险、重复、繁重的工业应用场景,有望率先实现具身智能赋能与落 地。 滑费:5月社零提速彰显国补刺激、新消费活跃。5月社零增长提速，受益于 ...

Core Viewpoint - The Hong Kong stock market's new consumption sector is experiencing a cooling period after a previous surge, with significant declines in the stock prices of key players in this sector. Group 1: Market Performance - The "new consumption trio" consisting of Lao Pu Gold, Pop Mart, and Mixue Group saw their stock prices drop significantly, with declines of 6.67%, 6.04%, and 5.85% respectively [2][3]. - Other companies in the sector, such as Bruker and Juzhibio, also faced declines, with Bruker dropping over 7% and Juzhibio nearly 5% [3][4]. - Year-to-date, Lao Pu Gold has increased by over 276%, Pop Mart by over 191%, and Mixue Group by over 158%, with a combined market capitalization exceeding 690 billion HKD [11][12]. Group 2: Market Dynamics - The new consumption sector experienced a strong rally earlier this year, with a reported increase of over 55% from April 7 to June 11, significantly outperforming internet giants during the same period [9]. - The influx of capital from southbound funds into the new consumption sector amounted to 18.325 billion HKD, marking it as a crucial source of incremental funding [9]. Group 3: Market Sentiment and Analysis - Analysts have raised concerns about the overheated nature of the new consumption market, suggesting that stock prices may be inflated beyond reasonable valuations [15][16]. - Factors contributing to the rise of new consumption include changing demographics, particularly the spending power of Generation Z, and a shift towards more frequent, smaller discretionary purchases due to slower income growth [15]. - Some analysts believe that the current market for innovative drugs and new consumption may have reached a peak, indicating potential volatility or adjustments ahead [17][18].

各位投资者朋友们周一上午好也是不好意思我们刚才出现了一些技术上的困难所以说今天的webcast有所延迟那也是再次欢迎大家来到了每周一度的大幕宏观策略团我是蔡志鹏那Robin总这周是在休假但是呢他在休假前已经就北京之行的所得和团队有了一些充分的交流那本期节目呢是由我代为主持那中国宏观经济在最近的几周大致是比较的平稳 关税对于经济的影响存在一定的滞后而财政的政策的前置也是有助于延续了九二四政策转向以来的一些政策脉冲所以说我们今天就聚焦三大边际上的一些变化也分别对应了投资者朋友们比较关心的几个话题分别是中美贸易磋商的新进展消费品已就换新政策的调整以及中办和国办发布的进一步改善社保体系的一个意见 那这三个边际上的变化对于短期的贸易局势以及中长期中国走出通缩的探索有什么意义那这个是宏观层面要探讨的问题那今天和往常一样呢我们也邀请到了中国首席股票策略师LauraLaura在发布了年终展望之后呢也是进行了一轮又一轮的紧锣密鼓的路演上周也是参加了大摩的澳大利亚峰会 那今天也是欢迎Laura带来最新的投资者反馈包括在地缘政治风险之下对于股票的配置会如何看待那我们今天的还邀请到了大中华消费团队的首席Lillian也会跟大家分享最 ...

Core Insights - The article highlights the launch of the "High-Quality Consumption Observation" series by Southern Metropolis Daily, focusing on nine popular consumption sectors including beauty economy, sports and outdoor, food and health, smart consumer electronics, pet economy, experience economy, interest consumption, cross-border e-commerce, and consumption technology [1] - The report indicates a significant growth trend in the beauty and personal care market, particularly in the skincare segment, with a year-on-year retail sales increase of 4.4% in May and 4.1% from January to May [1] - The article emphasizes the shift towards efficacy-driven skincare products, with consumers increasingly demanding solutions for specific skin issues, leading to a notable rise in sales for products like sunscreen and hair care [1][12] Industry Trends - The beauty industry is witnessing a rise in "ingredient-focused" marketing, with brands emphasizing core ingredients to meet consumer demands for efficacy [11][25] - The competition in the high-end cosmetics market is intensifying, with international brands re-entering the Chinese market and dominating sales rankings during major promotional events like the 618 shopping festival [30][31] - Online sales channels have surpassed 50% of the market share in the cosmetics industry, with brands increasingly relying on e-commerce platforms for revenue growth [22][24] Brand Performance - Notable brands such as Proya and Han Shu have reported significant revenue growth, with Proya achieving over 10.7 billion yuan in 2024, while Han Shu's sales on Douyin reached 6.7 billion yuan [35][36] - The article mentions that brands like Huaxi Biological and Juzhibio have seen substantial revenue increases, with Juzhibio's revenue growing by 57.2% to 5.54 billion yuan in 2024 [7][33] - The performance of brands is increasingly tied to their ability to innovate and effectively market their products, particularly in the context of ingredient transparency and efficacy claims [11][25] Consumer Behavior - Consumers are becoming more rational in their purchasing decisions, focusing on product efficacy, ingredient transparency, and value for money, which is pushing brands to invest more in research and development [25][26] - The demand for specific skincare solutions, such as anti-aging and repair products, is driving growth in niche markets within the beauty sector [12][25] - The rise of content-driven e-commerce, including live streaming and social media sales, is reshaping how beauty brands engage with consumers and drive sales [24][30]

Investment Rating - The report suggests a positive outlook for the consumer sector, particularly benefiting from government subsidies and new consumption trends [4][5][46]. Core Insights - The acceleration in retail sales in May is attributed to national subsidies, new consumption patterns, and the early start of the 618 shopping festival [4][7]. - Concerns exist regarding the continuity of national subsidies, while new consumption trends are gaining more attention due to their high growth potential [2][14]. - The overall retail sales growth is primarily supported by consumption subsidy policies, although underlying consumer demand remains weak [4][12]. Summary by Sections Retail Sales Performance - In May 2025, retail sales grew by 6.4% year-on-year, with a total of 41,326 billion yuan, while the cumulative retail sales from January to May increased by 5.0% to 203,171 billion yuan [15]. - The retail sales growth rates for various categories in May include: - Home appliances: +53.0% - Communication equipment: +33.0% - Cultural and office supplies: +30.5% - Furniture: +25.6% [16][24]. Consumer Segments - New consumption sectors, such as new tea drinks and sports entertainment products, are showing significant growth, with May retail sales for sports and entertainment items increasing by 28.3% year-on-year [13][18]. - The gold and jewelry sector also saw a rise in retail sales by 12.3% from January to May, driven by the demand for value preservation amid rising gold prices [13][16]. Government Subsidies - The government has allocated 1,500 billion yuan for consumer subsidies in 2024 and 3,000 billion yuan in 2025, enhancing the impact of these subsidies on consumer spending [4][34]. - The report highlights that the effectiveness of these subsidies is expected to continue in the first half of 2025, although there may be limitations on the subsidy amounts in the latter half of the year [12][34]. Investment Recommendations - The report recommends investments in various sectors, including: - Consumer services: Gu Ming, Mi Xue Group - Food and beverage: Dongpeng Beverage, Qingdao Beer - Pet industry: Guibao Pet, Petty Co., Ltd. - Home appliances: Midea Group, Hisense Visual [46].